PainReform Ltd. (NASDAQ:PRFX) Sees Significant Increase in Short Interest

PainReform Ltd. (NASDAQ:PRFX – Get Free Report) saw a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 313,070 shares, a growth of 324.9% from the May 14th total of 73,684 shares. Approximately 54.9% of the company’s shares are short sold. Based on an average daily trading volume, of 8,718,443 shares, the short-interest ratio is presently 0.0 days.

PainReform Stock Down 4.5%

PRFX stock traded down $0.07 during trading on Thursday, hitting $1.48. The company had a trading volume of 103,976 shares, compared to its average volume of 1,353,102. The firm has a market capitalization of $1.29 million, a P/E ratio of 0.00 and a beta of 0.98. PainReform has a 52-week low of $1.28 and a 52-week high of $17.95. The company has a 50 day simple moving average of $2.01 and a 200-day simple moving average of $3.07.

Get PainReform alerts:

PainReform (NASDAQ:PRFX – Get Free Report) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($1.01) EPS for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, PainReform presently has a consensus rating of “Sell”.

Get Our Latest Stock Report on PainReform

About PainReform

(Get Free Report)

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.

Read More

• Five stocks we like better than PainReform
• Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
• NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
• The World Cup Is Coming—These 3 Stocks Could Cash In
• Spotify’s “North Star” Outlook Was Music to Investors Ears

Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.